Income Statement (TTM)
Tryptamine Therapeutics Limited Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2024 06-30 |
2025 06-30 |
|
|---|---|---|
| Revenue | 1 | 2 |
| Change (%) | 19.17 | |
| % of Revenue | 100.00 | 100.00 |
| Cost Of Sales | 2 | 2 |
| Change (%) | 2.19 | |
| % of Revenue | 176.85 | 151.65 |
| Gross Operating Profit | -1 | -1 |
| Change (%) | -19.91 | |
| % of Revenue | -76.85 | -51.65 |
| SG&A | 3 | 4 |
| Change (%) | 22.56 | |
| % of Revenue | 262.91 | 270.40 |
| R&D | ||
| Change (%) | ||
| % of Revenue | ||
| OpEx | 6 | 7 |
| Change (%) | 15.14 | |
| % of Revenue | 440.38 | 425.49 |
| Operating Income | -5 | -5 |
| Change (%) | 13.96 | |
| % of Revenue | -340.38 | -325.49 |
| Interest Expense | -1 | -0 |
| Change (%) | -98.83 | |
| % of Revenue | -48.84 | -0.48 |
| Net Income | -7 | -5 |
| Change (%) | -27.66 | |
| % of Revenue | -555.37 | -337.14 |
Source: Capital IQ
